Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update

Rhythm posts strong IMCIVREE revenue growth, secures $750M facility, and restructures key royalty deal.

What the company is saying

Rhythm Pharmaceuticals is emphasizing robust commercial momentum for IMCIVREE, particularly in the U.S., with sequential and year-over-year revenue growth. Management, led by CEO David Meeker, frames the U.S. launch as validation of unmet need and market opportunity in acquired hypothalamic obesity. The company highlights international expansion, citing the commercial launch in Japan, regulatory approvals in Canada, Japan, and the UK, and plans for further European rollouts. Rhythm spotlights its strengthened capital position via a new five-year, $750 million term loan facility led by KKR's HealthCare Royalty and Blackstone Life Sciences. The company also stresses the strategic restructuring of its LG Chem royalty agreement, reducing future royalties to 1% in exchange for $350 million in fixed payments over four years. The tone is confident, with management attributing revenue growth to increased patient demand and positioning the pipeline—particularly bivamelagon and RM-718—as drivers of future value.

What the data suggests

IMCIVREE global sales reached $92.1 million in Q3 2026, up 29% sequentially and nearly 80% year-over-year from $51.3 million in Q3 2025. U.S. revenue was $67.5 million (73% of total), increasing $16.5 million or 32% from Q2 2026, while ex-U.S. revenue was $24.7 million, up $4.4 million or 22%. The number of patients on reimbursed therapy globally rose 20% quarter-over-quarter, though absolute patient counts are not disclosed. Operating expenses also increased: R&D was $52.5 million (vs $46.0 million Q3 2025), and SG&A was $66.8 million (vs $52.4 million). Net loss narrowed to $(42.4) million ($(0.61) per share) from $(54.3) million ($(0.82) per share) a year ago. Cash and equivalents were $320.9 million at September 30, 2026, not including a $250 million initial loan draw or a $70 million payment due to LG Chem. The company expects $360–$380 million in non-GAAP operating expenses for 2026, with cash runway for at least 24 months. The $350 million royalty buyout reduces future royalties to 1% but represents a major near-term cash commitment. The company is executing on international launches and advancing late-stage clinical programs, but the financials show continued operating losses despite revenue growth.

Analysis

The announcement is generally positive, with strong realised revenue growth (Q3 2026 IMCIVREE sales up 29% sequentially and 80% year-over-year) and improved net loss figures. The company discloses detailed financials, including net loss, R&D, and SG&A, meeting the disclosure completeness rule. However, the tone is somewhat inflated by highlighting large capital access ($750M term loan facility) and a $350M royalty buyout, both of which are significant outlays with long-term implications, while the immediate earnings impact is not quantified. Some operational claims (e.g., patient growth, regulatory approvals) lack absolute numbers or supporting documentation. The majority of key claims are realised and supported by numbers, but the announcement also emphasizes future milestones and guidance, which are inherently forward-looking. The gap between narrative and evidence is moderate: realised financial progress is clear, but the scale of capital commitments and future milestones is presented optimistically without full detail on risk or timing.

Risk flags

• ●The $750 million term loan facility adds significant leverage, increasing financial risk if revenue growth slows or operating losses persist; repayment obligations could constrain future flexibility.
• ●The $350 million fixed payment to LG Chem over four years is a substantial cash outlay, and while it reduces future royalties to 1%, the payback period and impact on profitability are not quantified, introducing uncertainty around the financial benefit.
• ●Despite strong revenue growth, the company remains loss-making, with net losses of $(42.4) million in Q3 2026 and ongoing high R&D and SG&A expenses; sustained losses could pressure liquidity if commercial momentum falters.
• ●International expansion and new product launches, such as in Japan and planned European rollouts, carry execution risk, including regulatory, reimbursement, and market uptake uncertainties, especially as no initial sales or patient uptake data for these new markets are disclosed.
• ●Pipeline advancement is critical to long-term value, but pivotal trials for bivamelagon and RM-718 are not yet initiated, and clinical or regulatory setbacks could delay or impair future revenue streams.

Bottom line

Rhythm Pharmaceuticals is delivering strong IMCIVREE revenue growth, especially in the U.S., and has secured substantial capital access with a $750 million term loan facility. The company is making aggressive moves to reduce future royalty burdens by committing $350 million in fixed payments to LG Chem, but this creates near-term cash flow pressure. While the financial disclosures are detailed and show improving losses, Rhythm remains unprofitable and is increasing its operating expense base to support international launches and late-stage pipeline development. Execution risk is elevated as the company expands into new markets and advances pivotal trials, with no immediate sales data from recent launches in Japan or Canada. The most important takeaway is that Rhythm is scaling rapidly and investing for future growth, but the path to profitability depends on continued commercial uptake and successful pipeline execution. Investors should focus on realized sales growth, cash burn, and the pace of international and pipeline milestones in upcoming quarters.

Announcement summary

(NASDAQ:RYTM) Rhythm Pharmaceuticals, Inc. reported financial results and provided a business update for the third quarter ended September 30, 2026. The company secured a five-year term loan facility led by KKR's HealthCare Royalty in partnership with Blackstone Life Sciences, providing access to up to $750 million of capital. Rhythm announced it has received more than 700 patient start forms for IMCIVREE for acquired hypothalamic obesity (HO) from more than 500 prescribers as of September 30, 2026, following FDA approval on March 19, 2026. Revenue from global sales of IMCIVREE was $92.1 million for the third quarter of 2026, an increase of 29% on a sequential basis from the second quarter of 2026. The number of patients on reimbursed therapy globally increased by 20% compared to the second quarter of 2026. U.S. revenue was $67.5 million, or 73% of product revenue, in the third quarter of 2026, an increase of $16.5 million or 32% compared to the second quarter of 2026. Ex-U.S. revenue was $24.7 million, or 27% of product revenue, a sequential increase of $4.4 million or 22% compared to the second quarter of 2026. Five presentations related to IMCIVREE and setmelanotide were accepted for ObesityWeek 2026. On November 2, 2026, Rhythm amended its exclusive license agreement with LG Chem for bivamelagon, agreeing to pay LG Chem $350 million in fixed payments over four years to reduce the royalty to 1% on net product revenue from Rhythm’s MC4R portfolio. The company launched IMCIVREE commercially in Japan on October 13, 2026, and received Health Canada approval for IMCIVREE on September 22, 2026. Rhythm presented six abstracts at the 64th Annual European Society for Paediatric Endocrinology Meeting on September 10, 2026. Japan’s Ministry of Health, Labour and Welfare approved IMCIVREE for acquired HO in Japan on August 24, 2026. Manher (“AJ”) Joshi, M.D., was appointed Chief Medical Officer on August 17, 2026. IMCIVREE received expanded Marketing Authorization in the United Kingdom on August 11, 2026. As of September 30, 2026, cash, cash equivalents, and short-term investments were approximately $320.9 million, compared to $388.9 million as of December 31, 2025. These figures do not include the $250 million initial draw on the term loan facility or the $70 million payment due to LG Chem. Net product revenues from global sales of IMCIVREE were $92.1 million for Q3 2026, compared to $51.3 million for Q3 2025. R&D expenses were $52.5 million in Q3 2026, compared to $46.0 million in Q3 2025. SG&A expenses were $66.8 million for Q3 2026, compared to $52.4 million for Q3 2025. Other expense, net was $(1.5) million for Q3 2026, compared to $(0.1) million for Q3 2025. Net loss attributable to common stockholders was $(42.4) million for Q3 2026, or $(0.61) per share, compared to $(54.3) million, or $(0.82) per share, for Q3 2025. For the nine months ended September 30, 2026, net product revenues were $223.5 million, compared to $137.5 million for the same period in 2025. R&D expenses for the nine months were $137.6 million, compared to $125.3 million in 2025. SG&A expenses for the nine months were $197.8 million, compared to $137.5 million in 2025. Other income (expense), net was $(4.5) million for the nine months ended September 30, 2026, compared to $(3.6) million for the same period in 2025. For the year ending December 31, 2026, Rhythm anticipates approximately $360 million to $380 million in Non-GAAP Operating Expenses, including R&D expenses of approximately $165 million to $175 million and SG&A expenses of approximately $195 million to $205 million, excluding stock-based compensation. Rhythm expects its cash, cash equivalents, and short-term investments as of September 30, 2026, will be sufficient to fund planned operations for at least 24 months. The company plans to complete enrollment in the Phase 1/2, Part D trial evaluating RM-718 in PWS in the second half of 2026, initiate a pivotal Phase 3 trial evaluating bivamelagon in acquired HO by year-end 2026, complete enrollment in the setmelanotide substudy in congenital HO in 2027, begin country-level launches of IMCIVREE for acquired HO in Europe starting with Germany in 2027, and initiate a 6-month hyperphagia study to evaluate bivamelagon in PWS in 2027, pending FDA alignment.

Disagree with this article?